Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Eosinophil-derived neurotoxin: a novel biomarker for diagnosis and monitoring of asthma

  • Kim, Chang-Keun (Department of Pediatrics, Asthma & Allergy Center, Inje University Sanggye Paik Hospital)
  • Received : 2012.04.17
  • Accepted : 2012.08.09
  • Published : 2013.01.15
Download PDF
⟨ Previous Next ⟩

Abstract

Asthma is associated with increased levels of eosinophils in tissues, body fluids, and bone marrow. Elevated levels of eosinophil-derived neurotoxin (EDN) and eosinophil cationic protein (ECP) have been noted in asthma patients. Higher levels of EDN and ECP are also associated with exacerbated asthmatic conditions. Thus, EDN, along with ECP, may aid the diagnosis and monitoring of asthma. Several groups have suggested that EDN is more useful than ECP in evaluating disease severity. This may partially be because of the recoverability of EDN (not sticky, 100% recovery rate), as ECP is a sticky and more highly charged protein. In terms of clinical utility, EDN level is a more accurate biomarker than ECP when analyzing the underlying pathophysiology of asthma. As a monitoring tool, EDN has shown good results in children with asthma as well as other allergic diseases. In children too young to fully participate in lung function tests, EDN levels may be useful as an alter native measurement of eosinophilic inflammation. EDN can also be used in adult patients and in multiple specimen types (e.g., serum, sputum, bronchoalveolar lavage fluid, and nasal lavage fluid). These results are repeatable and reproducible. In conclusion, EDN may be a novel biomarker for the diagnosis, treatment, and monitoring of asthma/allergic disease.

Keywords

References

  1. Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008;38:709-50. https://doi.org/10.1111/j.1365-2222.2008.02958.x
  2. The Global Initiative for Asthma. GINA report, global strategy for asthma management and prevention. Updated Dec. 2011 [Internet]. [place unknown]: The Global Initiative For Asthma; c2011. [cited 2011 Jun 21]. Available from: http://www.ginasthma.org/guidelinesgina- report-global-strategy-for-asthma.html.
  3. British Thoracic Society. 2008 British guideline on the management of asthma: a national clinical guideline. Updated Jun. 2009 [Internet]. London: British Thoracic Society; c2011 [cited 2011 Jun 21]. Available from: http://www.brit-thoracic.org.uk/guidelines/ asthma-guidelines.aspx.
  4. Crimi E, Spanevello A, Neri M, Ind PW, Rossi GA, Brusasco V. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. Am J Respir Crit Care Med 1998;157:4-9. https://doi.org/10.1164/ajrccm.157.1.9703002
  5. Parameswaran K, Pizzichini E, Pizzichini MM, Hussack P, Efthimiadis A, Hargreave FE. Clinical judgement of airway inflammation versus sputum cell counts in patients with asthma. Eur Respir J 2000;15:486-90. https://doi.org/10.1034/j.1399-3003.2000.15.10.x
  6. Pizzichini MM, Pizzichini E, Clelland L, Efthimiadis A, Pavord I, Dolovich J, et al. Prednisone-dependent asthma: inflammatory indices in induced sputum. Eur Respir J 1999;13:15-21. https://doi.org/10.1183/09031936.99.13101599
  7. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000;161:64-72. https://doi.org/10.1164/ajrccm.161.1.9809100
  8. Venge P. Monitoring the allergic inflammation. Allergy 2004;59: 26-32. https://doi.org/10.1046/j.1398-9995.2003.00386.x
  9. Gleich GJ, Adolphson CR. The eosinophil and bronchial asthma: evidence for a critical role of eosinophils in pathophysiology. In: Sanderson CJ, editor., Interleukin-5: from molecule to drug target for asthma (lung biology in health disease). New York: Marcel Dekker, 1999:1-37.
  10. Kim KW, Lee KE, Kim ES, Song TW, Sohn MH, Kim KE. Serum eosinophil-derived neurotoxin (EDN) in diagnosis and evaluation of severity and bronchial hyperresponsiveness in childhood asthma. Lung 2007;185:97-103. https://doi.org/10.1007/s00408-006-0054-8
  11. Taniuchi S, Chihara J, Kojima T, Yamamoto A, Sasai M, Kobayashi Y. Serum eosinophil derived neurotoxin may reflect more strongly disease severity in childhood atopic dermatitis than eosinophil cationic protein. J Dermatol Sci 2001;26:79-82. https://doi.org/10.1016/S0923-1811(00)00151-1
  12. Wilson NM, Bridge P, Spanevello A, Silverman M. Induced sputum in children: feasibility, repeatability, and relation of findings to asthma severity. Thorax 2000;55:768-74. https://doi.org/10.1136/thorax.55.9.768
  13. Wojnarowski C, Roithner B, Koller DY, Halmerbauer G, Gartner C, Tauber E, et al. Lack of relationship between eosinophil cationic protein and eosinophil protein X in nasal lavage and urine and the severity of childhood asthma in a 6-month follow-up study. Clin Exp Allergy 1999;29: 926-32. https://doi.org/10.1046/j.1365-2222.1999.00586.x
  14. Gleich GJ, Adolphson CR. The eosinophilic leukocyte: structure and function. Adv Immunol 1986;39:177-253. https://doi.org/10.1016/S0065-2776(08)60351-X
  15. Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Peterson C, et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 1999;29:1172-86. https://doi.org/10.1046/j.1365-2222.1999.00542.x
  16. Goto T, Morioka J, Inamura H, Yano M, Kodaira K, Igarashi Y, et al. Urinary eosinophil-derived neurotoxin concentrations in patients with atopic dermatitis: a useful clinical marker for disease activity. Allergol Int 2007;56:433-8. https://doi.org/10.2332/allergolint.O-07-489
  17. Koller DY, Halmerbauer G, Frischer T, Roithner B. Assessment of eosinophil granule proteins in various body fluids: is there a relation to clinical variables in childhood asthma? Clin Exp Allergy 1999;29:786-93. https://doi.org/10.1046/j.1365-2222.1999.00546.x
  18. Harrison AM, Bonville CA, Rosenberg HF, Domachowske JB. Respiratory syncytical virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. Am J Respir Crit Care Med 1999;159:1918-24. https://doi.org/10.1164/ajrccm.159.6.9805083
  19. Kim CK, Choi J, Kim HB, Callaway Z, Shin BM, Kim JT, et al. A randomized intervention of montelukast for post-bronchiolitis: effect on eosinophil degranulation. J Pediatr 2010;156:749-54. https://doi.org/10.1016/j.jpeds.2009.12.001
  20. Papadopoulos NG, Papi A, Meyer J, Stanciu LA, Salvi S, Holgate ST, et al. Rhinovirus infection up-regulates eotaxin and eotaxin-2 expression in bronchial epithelial cells. Clin Exp Allergy 2001;31: 1060-6. https://doi.org/10.1046/j.1365-2222.2001.01112.x
  21. Choi EH, Lee HJ, Yoo T, Chanock SJ. A common haplotype of interleukin- 4 gene IL4 is associated with severe respiratory syncytial virus disease in Korean children. J Infect Dis 2002;186: 1207-11. https://doi.org/10.1086/344310
  22. Parkin PC, Macarthur C, Saunders NR, Diamond SA, Winders PM. Development of a clinical asthma score for use in hospitalized children between 1 and 5 years of age. J Clin Epidemiol 1996;49: 821-5. https://doi.org/10.1016/0895-4356(96)00027-3
  23. Kim CK, Callaway Z, Fletcher R, Koh YY. Eosinophil-derived neurotoxin in childhood asthma: correlation with disease severity. J Asthma 2010;47:568-73. https://doi.org/10.3109/02770901003792833
  24. Kim CK, Kita H, Callaway Z, Kim HB, Choi J, Fujisawa T, et al. The roles of a Th2 cytokine and CC chemokine in children with stable asthma: potential implication in eosinophil degranulation. Pediatr Allergy Immunol 2010;21(4 Pt 2):e697-704. https://doi.org/10.1111/j.1399-3038.2010.01047.x
  25. Kim CK, Callaway Z, Kim DW, Kita H. Eosinophil degranulation is more important than eosinophilia in identifying asthma in chronic cough. J Asthma 2011;48:994-1000. https://doi.org/10.3109/02770903.2011.623335

Cited by

  1. Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels vol.13, pp.9, 2013, https://doi.org/10.1517/14712598.2013.819338
  2. Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1β and sCD200 in cases of Samter's syndrome: 36 months follow-up vol.35, pp.4, 2013, https://doi.org/10.3109/08923973.2013.811598
  3. Exhaled nitric oxide and nasal tryptase are associated with wheeze, rhinitis and nasal allergy in primary school children vol.19, pp.6, 2013, https://doi.org/10.3109/1354750x.2014.937362
  4. Eosinophil-Derived Neurotoxin (EDN/RNase 2) and the Mouse Eosinophil-Associated RNases (mEars): Expanding Roles in Promoting Host Defense vol.16, pp.12, 2013, https://doi.org/10.3390/ijms160715442
  5. Serum Levels of Eosinophil-Derived Neurotoxin: A Biomarker for Asthma Severity in Adult Asthmatics vol.11, pp.3, 2019, https://doi.org/10.4168/aair.2019.11.3.394
  6. Phenotypes of the inflammatory cells in the induced sputum from young children or infants with recurrent wheezing vol.85, pp.4, 2019, https://doi.org/10.1038/s41390-018-0268-5
  7. Analysis of the predicting factors of recurrent wheezing in infants vol.45, pp.1, 2013, https://doi.org/10.1186/s13052-019-0609-y
  8. Montelukast use over the past 20 years: monitoring of its effects and safety issues vol.63, pp.10, 2020, https://doi.org/10.3345/cep.2019.00325
  9. Comparison of serum eosinophil-derived neurotoxin levels between wheezing and non-wheezing groups in children with respiratory tract infection vol.57, pp.11, 2013, https://doi.org/10.1080/02770903.2019.1642349
  10. Eosinophil-derived neurotoxin: A biologically and analytically attractive asthma biomarker vol.16, pp.2, 2013, https://doi.org/10.1371/journal.pone.0246627
  11. Changes in Type 2 Biomarkers After Anti-IL5 Treatment in Patients With Severe Eosinophilic Asthma vol.13, pp.2, 2021, https://doi.org/10.4168/aair.2021.13.2.330